Loading
A phase 2 trial of ivonescimab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT06944106 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 30 participants, started 2025-03-28 and due to reach its primary completion in 2026-04-28. Interventions recorded: AK112. Conditions listed: Pancreatic Cancer. Primary outcome: R0 and R1 resection rates. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic cancer". Sites: China. No results are recorded here; the registry entry is the source.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.